IDBS and Alchemi say AI agents can draft pharma technical reports up to 70% faster, but the speed figure is the vendors' own, and a human still signs off.
Biopharma companies spend months assembling manufacturing data, drafting regulatory reports, and reconstructing process histories for every filing they send to regulators. Most current AI tools cannot help, because the tools break the validated-data compliance chain by pulling data out of governed systems.
That is the structural problem a new partnership between IDBS, a Danaher-owned data platform, and Alchemi, an applied-AI vendor, says it wants to solve. Announced on 2026-06-16, the deal connects Alchemi's AI agents to the IDBS Polar platform, the data foundation that underpins IDBS's "Lab Loop" concept for drug development, with the stated goal of drafting chemistry, manufacturing, and controls (CMC) technical reports, clinical study reports, and full submission dossiers, according to the joint announcement.
The architectural argument matters more than the speed number. Most AI tools a regulatory team might use today sit outside the validated data backbone: they pull from a copy, summarize, and produce text that is no longer traceable to the original system of record. For a CMC or clinical study report that has to survive a 21 CFR Part 11 audit, the U.S. Food and Drug Administration rule that requires electronic records to be trustworthy, traceable, and signed off by a human, that is a hard stop. IDBS and Alchemi say their agents keep working inside the validated data environment, with drafts routed through human-in-the-loop review and sign-off, so every line stays traceable to a source record in the audit trail, per the release.
That distinction is also where the headline-grabbing speed claim has to land carefully. Alchemi says that, in its own customer deployments, teams have produced documents of this type "up to 70% faster" using its agents. The press release does not define the baseline, the document mix, or the deployment count, and the number reflects Alchemi's characterization of its own work, not independent measurement. The press release is about how fast an agent can produce a draft document that humans will review and sign. It is not a claim about faster regulator decisions or shorter review clocks at the FDA, and any reading of the partnership that lets "submission-ready quality" collapse into "faster approvals" loses the plot, per the release.
The announcement also does not name an independent practitioner, customer, or former regulator. The partnership is real, the architecture is real, and the 70% figure is a vendor-attested number from a joint PR Newswire distribution. What is not yet in the record is how a regulatory affairs lead, a CMC writer, or a former FDA reviewer reads the workflow, or how a named IDBS Polar customer using Alchemi in production would describe the speedup in their own environment.
Watch next: whether IDBS or Alchemi names a customer reference, whether a former reviewer weighs in on whether human-in-the-loop drafting inside a Part 11 audit trail changes the review burden, and whether the 70% figure is ever restated with a baseline and document-type breakdown. Until then, the partnership is best read as one concrete instance of a structural question: can agentic AI live inside the compliance chain that regulated industries have spent two decades building, or only next to it?